Prognostic Value of Initial Tumor Parameters After Metastatic Relapse

REFERENCES

• Tacca O, LeHeurteur M, Durando X, Mouret-Reynier MA, Abrial C, Thivat E, Bayet-Robert M, Penault-Llorca F, Chollet P. Metastatic breast cancer: overall survival related to successive chemotherapies. What do we gain after the third line? Cancer Invest 2009;27:81–85.
   PubMed Web of Science ®Google Scholar
• Giordano SH, Buzdar AU, Smith TL, Kau, SW, Yang, Y, Hortobagyi GN. Is breast cancer survival improving? Cancer 2004;100:44–52.
   PubMed Web of Science ®Google Scholar
• Amat, S, Penault-Llorca F, Cure H, Le Bouedëc G, Achard JL, Van Praagh I, Feillel V, Mouret-Reynier MA, Dauplat J, Chollet P. Scarff–Bloom–Richardson (SBR) grading: a pleiotropic marker of chemosensitivity in invasive ductal breast carcinomas treated by neoadjuvant chemotherapy. Int J Oncol 2002;20:791–796.
   PubMed Web of Science ®Google Scholar
• Le Doussal V, Tubiana-Hulin M, Friedman S, Hacene K, Spyratos F, Brunet M. Prognostic value of histologic grade nuclear components of Scarff–Bloom–Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer 1989;64:1914–1921.
   PubMed Web of Science ®Google Scholar
• Beenken SW, Urist MM, Zhang Y, Desmond R, Krontiras H, Medina H, Bland KI. Axillary lymph node status, but not tumor size, predicts locoregional recurrence and overall survival after mastectomy for breast cancer. Ann Surg 2003;237:732–738.
   PubMed Web of Science ®Google Scholar
• Blamey RW, Ellis IO, Pinder SE, Lee AH, Macmillan RD, Morgan DA, Robertson JF, Mitchell MJ, Ball GR, Haybittle JL, Elston CW. Survival of invasive breast cancer according to the Nottingham Prognostic Index in cases diagnosed in 1990–1999. Eur J Cancer 2007;43:1548–1555.
   PubMed Web of Science ®Google Scholar
• Yankaskas BC. Epidemiology of breast cancer in young women. Breast Dis 2005;23:3–8.
   PubMedGoogle Scholar
• Albain KS, Allred DC, Clark GM. Breast cancer outcome and predictors of outcome: are there age differentials? J Natl Cancer Inst Monogr 1994;16:35–42.
   PubMedGoogle Scholar
• Tacca O, Penault-Llorca F, Abrial C, Mouret-Reynier MA, Raoelfils I, Durando X, Achard JL, Gimbergues P, Curé H, Chollet P. Changes in and prognostic value of hormone receptor status in a series of operable breast cancer patients treated with neoadjuvant chemotherapy. Oncologist 2007;12:636–643.
   PubMed Web of Science ®Google Scholar
• Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007;13:2329–2334.
   PubMed Web of Science ®Google Scholar
• Penault-Llorca F, Cayre A, Bouchet Mishellany F, Amat S, Feillel V, Le Bouedec G, Ferrière JP, De Latour M, Chollet P. Induction chemotherapy for breast carcinoma: predictive markers and relation with outcome. Int J Oncol 2003;22:1319–1325.
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177–182.
   PubMed Web of Science ®Google Scholar
• Nicolini A, Giardino R, Carpi A, Ferrari P, Anselmi L, Colosimo S, Conte M, Fini M, Giavaresi G, Berti P, Miccoli P. Metastatic breast cancer: an updating. Biomed Pharmacother 2006;60:548–556.
   PubMed Web of Science ®Google Scholar
• Abrial SC, Penault-Llorca F, Delva R, Bougnoux P, Leduc B, Mouret-Reynier MA, Mery-Mignard D, Bleuse JP, Dauplat J, Curé H, Chollet P. High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer. Breast Cancer Res Treat 2005;94:255–263.
   PubMed Web of Science ®Google Scholar
• Penault-Llorca F, Abrial C, Raoelfils I, Chollet P, Cayre A, Mouret-Reynier MA, Thivat E, Mishellany F, Gimbergues P, Durando X. Changes and predictive and prognostic value of the mitotic index, Ki-67, cyclin D1, and cyclo-oxygenase-2 in 710 operable breast cancer patients treated with neoadjuvant chemotherapy. Oncologist 2008;13:1235–1245.
   PubMed Web of Science ®Google Scholar
• Adjuvant therapy for breast cancer. NIH Consens Statement 2000;17:1–35.
   Google Scholar
• Vorgias G, Koukouras D, Paleogianni V, Tzoracoeleftherakis E. Prognostic significance of factors affecting disease free interval and overall survival for Stage II breast cancer in Greece. A multivariate cohort study. Eur J Obstet Gynecol Reprod Biol 2001;95:100–104.
   PubMed Web of Science ®Google Scholar
• Martinez-Ramos D, Escrig-Sos J, Alcalde-Sanchez M, Torrella-Ramos A, Salvador-Sanchis JL. Disease-free survival and prognostic significance of metastatic lymph node ratio in T1-T2 N positive breast cancer patients. A population registry-based study in a European country. World J Surg 2009;33:1659–1664.
   PubMed Web of Science ®Google Scholar
• Yamamoto N, Watanabe T, Katsumata N, Omuro Y, Ando M, Fukuda H, Takue Y, Narabayashi M, Adachi I, Takashima S. Construction and validation of a practical prognostic index for patients with metastatic breast cancer. J Clin Oncol 1998;16:2401–2408.
   PubMed Web of Science ®Google Scholar
• Pierga JY, Robain M, Jouve M, Asselain B, Diéras V, Beuzeboc P, Palangié T, Dorval T, Extra JM, Scholl S, Pouillart P. Response to chemotherapy is a major parameter-influencing long-term survival of metastatic breast cancer patients. Ann Oncol 2001;12:231–237.
   PubMed Web of Science ®Google Scholar
• Clark GM, Sledge GW Jr, Osborne CK, McGuire WL. Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol 1987;5:55–61.
   PubMed Web of Science ®Google Scholar
• Spataro V, Price K, Goldhirsch A, Cavalli F, Simoncini E, Castiglione M, Rudenstam CM, Collins J, Lindtner J, Gelber RD. Sequential estrogen receptor determinations from primary breast cancer and at relapse: prognostic and therapeutic relevance. The International Breast Cancer Study Group (formerly Ludwig Group). Ann Oncol 1992;3:733–740.
   PubMed Web of Science ®Google Scholar
• Guarneri V, Bengala C, Orlandini C, Gennari A, Donati S, Campani D, Collecchi P, Maur M, Conte PF. HER2 overexpression as a prognostic factor in metastatic breast cancer patients treated with high-dose chemotherapy and autologous stem cell support. Bone Marrow Transplant 2004;34:413–417.
   PubMed Web of Science ®Google Scholar
• Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 2010;28:92–98.
   PubMed Web of Science ®Google Scholar
• Blanco G, Holli K, Heikkinen M, Kallioniemi OP, Taskinen P. Prognostic factors in recurrent breast cancer: relationships to site of recurrence, disease-free interval, female sex steroid receptors, ploidy and histological malignancy grading. Br J Cancer 1990;62:142–146.
   PubMed Web of Science ®Google Scholar
• Porter GJ, Evans AJ, Pinder SE, James JJ, Cornford EC, Burrell HC, Chan SY, Cheung KL, Robertson JF. Patterns of metastatic breast carcinoma: influence of tumour histological grade. Clin Radiol 2004;59:1094–1098.
   PubMed Web of Science ®Google Scholar
• Hietanen P, Miettinen M, Mäkinen J. Survival after first recurrence in breast cancer. Eur J Cancer Clin Oncol 1986;22: 913–919.
   PubMedGoogle Scholar
• Amat S, Abrial C, Penault-Llorca F, Delva R, Bougnoux P, Leduc B, Mouret-Reynier MA, Mery-Mignard D, Bleuse JP, Dauplat J, Curé H, Chollet P. High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer. Breast Cancer Res Treat 2005;94:255–263.
   PubMed Web of Science ®Google Scholar
• Dirier A, Burhanedtin-Zincircioglu S, Karadayi B, Isikdogan A, Aksu R. Characteristics and prognosis of breast cancer in younger women. J BUON 2009;14:619–623.
   PubMed Web of Science ®Google Scholar
• Altundag K, Bondy ML, Mirza NQ, Kau SW, Broglio K, Hortobagyi GN, Rivera E. Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis. Cancer 2007;110:2640–2647.
   PubMed Web of Science ®Google Scholar
• Manders K, Van de Poll-Franse LV, Creemers GJ, Vreugdenhil G, van der Sangen MJ, Nieuwenhuijzen GA, Roumen RM, Voogd AC. Clinical management of women with metastatic breast cancer: a descriptive study according to age group. BMC Cancer 2006;6:179.
   PubMedGoogle Scholar
• Largillier R, Ferrero JM, Doyen J, Barriere J, Namer M, Mari V, Courdi A, Hannoun-Levi JM, Ettore F, Birtwisle-Peyrottes I, Balu-Maestro C, Marcy PY, Raoust I, Lallement M, Chamorey E. Prognostic factors in 1,038 women with metastatic breast cancer. Ann Oncol 2008;19:2012–2019.
   PubMed Web of Science ®Google Scholar
• Puente J, López-Tarruella S, Ruiz A, Lluch A, Pastor M, Alba E, de la Haba J, Ramos M, Cirera L, Antón A, Llombart A, Plazaola A, Fernández-Aramburo A, Sastre J, Díaz-Rubio E, Martin M. Practical prognostic index for patients with metastatic recurrent breast cancer: retrospective analysis of 2,322 patients from the GEICAM Spanish El Alamo Register. Breast Cancer Res Treat 2010;122:591–600.
   PubMed Web of Science ®Google Scholar
• Broom RJ, Tang PA, Simmons C, Bordeleau L, Mulligan AM, O'Malley FP, Miller N, Andrulis IL, Brenner DM, Clemons MJ. Changes in estrogen receptor, progesterone receptor and HER-2/neu status with time: discordance rates between primary and metastatic breast cancer. Anticancer Res 2009;29:1557–1562.
   PubMed Web of Science ®Google Scholar
• Chollet P, Amat S, Belembaogo E, Curé H, de Latour M, Dauplat J, Le Bouëdec G, Mouret-Reynier MA, Ferrière JP, Penault-Llorca F. Is Nottingham prognostic index useful after induction chemotherapy in operable breast cancer? Br J Cancer 2003;89:1185–1191.
   PubMed Web of Science ®Google Scholar
• Pusztai L, Viale G, Kelly CM, Hudis CA. Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis. Oncologist 2010;15:1164–1168.
   PubMed Web of Science ®Google Scholar